Haiqing Liu

Dr. Haiqing Liu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
HLHaiqing Liu
Haiqing Liu
YTYanjun Tian
Yanjun Tian
BJBingyuan Ji
Bingyuan Ji
LHLu Hai
Lu Hai
QXQing Xin
Qing Xin
BBBo Bai
Bo Bai

3 March 2020 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
YTYanjun Tian
Yanjun Tian
RCRuijiao Chen
Ruijiao Chen
YJYunlu Jiang
Yunlu Jiang
BBBo Bai
Bo Bai
TYTongju Yang
Tongju Yang
HLHaiqing Liu
Haiqing Liu
The orphan receptor APJ and its endogenous ligand apelin, which are expressed in the brain, are the major components of the apelin/APJ system. Growing evidence shows that the apelin/APJ system plays a vital role in the pathophysiology of cerebral ischemic injury. Targeting the apelin/APJ system may have protective effects on cerebral ischemic injury. In this review, we sum up the latest research progress relating to the actions and therapeutic potential of the apelin/APJ system in ischemic stroke. An in-depth knowledge of the pathophysiological effects of the apelin/APJ system and the underlying mechanisms will help to develop novel therapeutic interventions for ischemic stroke.

10 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
YTYanjun Tian
Yanjun Tian
HLHaiqing Liu
Haiqing Liu
MWMengwei Wang
Mengwei Wang
RWRuihao Wang
Ruihao Wang
GYGuandong Yi
Guandong Yi
RCRuijiao Chen
Ruijiao Chen
Signal transducer and activator of transcription 3 (STAT3) and nuclear factor erythroid-derived 2-like 2 (NRF2, also known as NFE2L2), are two of the most complicated transcription regulators, which participate in a variety of physiological processes. Numerous studies have shown that they are overactivated in multiple types of tumors. Interestingly, STAT3 and NRF2 can also interact with each other to regulate tumor progression. Hence, these two important transcription factors are considered key targets for developing a new class of antitumor drugs. This review summarizes the pivotal roles of the two transcription regulators and their interactions in the tumor microenvironment to identify potential antitumor drug targets and, ultimately, improve patients’ health and survival.